Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.

ABSTRACT:

Background

As the COVID-19 pandemic continues to spread, the number of associated deaths continues to increase, especially among those with pre-existing conditions. Azvudine is recommended as a priority treatment for patients with COVID-19, but its efficacy in patients with pre-existing conditions is unknown.

Methods

This is a single-centre, retrospective cohort study between December 5, 2022 and January 31, 2023 in Xiangya Hospital of Central South University in China to evaluate the clinical efficacy of Azvudine in hospitalised patients with COVID-19 and pre-existing conditions. Patients with Azvudine and controls were propensity score-matched (1:1) for age, gender, vaccination status, time from symptom onset to treatment exposure, severity at admission, concomitant treatm

SUBMITTER: Sun Y 

PROVIDER: S-EPMC10167478 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature